[go: up one dir, main page]

WO2002013845A3 - Inflammation related g-protein coupled receptor - Google Patents

Inflammation related g-protein coupled receptor Download PDF

Info

Publication number
WO2002013845A3
WO2002013845A3 PCT/EP2001/009466 EP0109466W WO0213845A3 WO 2002013845 A3 WO2002013845 A3 WO 2002013845A3 EP 0109466 W EP0109466 W EP 0109466W WO 0213845 A3 WO0213845 A3 WO 0213845A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
coupled receptor
protein coupled
inflammation related
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/009466
Other languages
French (fr)
Other versions
WO2002013845A2 (en
Inventor
Gabor Jarai
Shida Yousefi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to JP2002518985A priority Critical patent/JP2004505648A/en
Priority to EP01980246A priority patent/EP1364017A2/en
Priority to AU2002212140A priority patent/AU2002212140A1/en
Publication of WO2002013845A2 publication Critical patent/WO2002013845A2/en
Anticipated expiration legal-status Critical
Publication of WO2002013845A3 publication Critical patent/WO2002013845A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprising as active ingredient (A) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:16 or a functionally equivalent variant of said amino acid sequence; or (B) a polynucleotide comprising a nucleotide sequence encoding the polypeptide (A); or (C) an antibody which is immunoreactive with the polypeptide (A); or (D) an antisense oligonucleotide comprising a nucleotide sequence complementary to that of polynucleotide (B); and the use of (A), (B), (C) and (D) in diagnostic and therapeutic applications.
PCT/EP2001/009466 2000-08-18 2001-08-16 Inflammation related g-protein coupled receptor Ceased WO2002013845A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002518985A JP2004505648A (en) 2000-08-18 2001-08-16 Inflammation-related G protein-coupled receptor
EP01980246A EP1364017A2 (en) 2000-08-18 2001-08-16 Inflammation related g-protein coupled receptor
AU2002212140A AU2002212140A1 (en) 2000-08-18 2001-08-16 Inflammation related g-protein coupled receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64165300A 2000-08-18 2000-08-18
US09/641,653 2000-08-18

Publications (2)

Publication Number Publication Date
WO2002013845A2 WO2002013845A2 (en) 2002-02-21
WO2002013845A3 true WO2002013845A3 (en) 2003-07-10

Family

ID=24573290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009466 Ceased WO2002013845A2 (en) 2000-08-18 2001-08-16 Inflammation related g-protein coupled receptor

Country Status (4)

Country Link
EP (1) EP1364017A2 (en)
JP (1) JP2004505648A (en)
AU (1) AU2002212140A1 (en)
WO (1) WO2002013845A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
EP1597587A2 (en) * 2003-02-17 2005-11-23 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US20060078916A1 (en) * 2004-08-27 2006-04-13 Luc Aguilar HM74 and HM74a in cuboidal endothelial cells as associated with inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056820A1 (en) * 1997-06-12 1998-12-17 Smithkline Beecham Corporation Hm74a receptor
WO2002018938A1 (en) * 2000-09-01 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056820A1 (en) * 1997-06-12 1998-12-17 Smithkline Beecham Corporation Hm74a receptor
WO2002018938A1 (en) * 2000-09-01 2002-03-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EL OUAKFAOUI SOUAD ET AL: "Granulocyte-macrophage colony-stimulating factor modulates tapasin expression in human neutrophils.", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 65, no. 2, February 1999 (1999-02-01), pages 205 - 210, XP002230379, ISSN: 0741-5400 *
NOMURA H ET AL: "MOLECULAR CLONING OF CDNAS ENCODING A LD78 RECEPTOR AND PUTATIVE LEUKOCYTE CHEMOTACTIC PEPTIDE RECEPTORS", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 5, no. 10, October 1993 (1993-10-01), pages 1239 - 1249, XP002911511, ISSN: 0953-8178 *
PALS CORNELIEKE E G M ET AL: "Identification of cytokine-regulated genes in human leukocytes in vivo.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 105, no. 4, April 2000 (2000-04-01), pages 760 - 768, XP008013156, ISSN: 0091-6749 *
YOUSEFI SHIDA ET AL: "cDNA representational difference analysis of human neutrophils stimulated by GM-CSF", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 277, no. 2, 22 October 2000 (2000-10-22), pages 401 - 409, XP002179732, ISSN: 0006-291X *

Also Published As

Publication number Publication date
EP1364017A2 (en) 2003-11-26
WO2002013845A2 (en) 2002-02-21
AU2002212140A1 (en) 2002-02-25
JP2004505648A (en) 2004-02-26

Similar Documents

Publication Publication Date Title
WO2001066597A3 (en) Inflammation-related gene
WO2000025725A3 (en) Functional antagonists of hedgehog activity
WO1998055508A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
EP2011510A3 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
WO2002022776A3 (en) Human coagulation factor vii variants
CA2529179A1 (en) Recombinant adeno-associated virus vector for treatment of alzheimer disease
EP1719780A3 (en) Mammalian cytokine-like polypeptide-10
WO1999006440A8 (en) Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
WO2003048205A3 (en) Novel proteins with il-6 inhibiting activity
EP1439231A3 (en) Amino-terminally truncated rantes as chemokine antagonists
CA2287534A1 (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
AU2002330289A1 (en) Preparation of a therapeutic composition
IT1299583B1 (en) USE OF HMG-I PROTEIN FOR THE PREPARATION OF MEDICATIONS WITH CYTOTOXIC ACTIVITY
WO2002013845A3 (en) Inflammation related g-protein coupled receptor
JP2003533188A5 (en)
WO2001049711A3 (en) Nucleic acids encoding (poly)peptides having chips activity
JP2006505290A5 (en)
WO2003097677A3 (en) Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus
CA2205564A1 (en) Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
CA2210871A1 (en) Human dnase i variants
WO2000068259A3 (en) Vaccine
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
WO2002048182A3 (en) Interferon-alpha induced gene
CA2397789A1 (en) Novel human kinase protein and polynucleotides encoding the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001980246

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002518985

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001980246

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001980246

Country of ref document: EP